Novatek Pharmaceuticals

Novatek Pharmaceuticals

Early Stage

Development of immunomodulatory drugs

Development of immunomodulatory drugs


Funding data not publicly available

Dealmaker Securities

Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common


Series A

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Pearland, Texas

Business Type


Novatek Pharmaceuticals, with a valuation of $5 million, is raising funds on Dealmaker Securities. It is a pharmaceutical company focused on the development of immunomodulatory drugs related to cancers and infectious diseases. The aim of Novatek Pharmaceuticals’ investigations is to develop drugs to empower naturally-derived immunotherapy and reduce the adverse effects of disease and cytotoxic therapies. Novatek Pharmaceuticals is led by an experienced team and has several products in clinical trials. Mohamed Kaseb founded Novatek Pharmaceuticals in April 2020. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $5 million. The campaign proceeds will be used for marketing, research and development, manufacturing, and general working capital.

Summary Profit and Loss Statement

FY 2021 FY 2020












Net Income



Summary Balance Sheet

FY 2021 FY 2020




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 01/03/2023
Create a free account today to gain access to KingsCrowd analytics.

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Novatek Pharmaceuticals on Dealmaker Securities 2023
Platform: Dealmaker Securities
Security Type: Equity - Common
Valuation: $5,000,000
Price per Share: $2.00

Follow company

Follow Novatek Pharmaceuticals on Dealmaker Securities 2023

Buy Novatek Pharmaceuticals's Deal Report

Warning: according to the close date for this deal, Novatek Pharmaceuticals may no longer be accepting investments.

Novatek Pharmaceuticals Deal Report

Get KingsCrowd’s comprehensive report on Novatek Pharmaceuticals including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Novatek Pharmaceuticals is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Novatek Pharmaceuticals deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge